About 9 results found for searched term "80-35-3" (0.116 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2746 | GW6471 | PPAR |
| GW6471 is an antagonist of PPARα with IC50 of 0.24 μM. | ||
| M5979 | Sulfamethoxypyridazine | PD-1/PD-L1 |
| CL 13494 | ||
| Sulfamethoxypyridazine is a long-acting sulfonamide for treatment of Dermatitis herpetiformis. | ||
| M21144 | JNJ-61803534 | Others |
| JNJ-61803534 is an orally active RORgt inhibitor, JNJ-61803534 is an oral clinical candidate that is well tolerated in humans up to 200 mg and has shown PD. | ||
| M29017 | JNJ-61803534 | ROR |
| JNJ-61803534 is a potent and orally active RORγt inverse agonist with an IC50 of 9.6 nM. JNJ-61803534 has anti-inflammatory activity. JNJ-61803534 inhibits IL-17A production in human CD4+ T cells under Th17 differentiation conditions. | ||
| M3552 | PHA-680632 | Aurora Kinase |
| PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. | ||
| M7041 | NPPB | Chloride Channel |
| Hoechst 144; HOE 144 | ||
| NPPB is a blocker of the outwardly rectifying chloride channel (ORCC) with IC50 of 80 nM. NPPB has been shown to activate the GPR35-Gαi/o and GPR35-Gα16 pathways in HEK293 cells, inducing intracellular calcium mobilization. | ||
| M20549 | GSK 5959 | Epigenetic Reader Domain |
| GSK5959 is a potent and selective BRPF1 bromodomain inhibitor with an IC50 of 80 nM and exhibits >100-fold selectivity for BRPF1 over a panel of 35 other bromodomains, including BRPF2/3 and BET family bromodomains. | ||
| M28725 | KMN-80 | Prostaglandin Receptor |
| KMN-80, a derivative of PGE1, is a selective and potent agonist of EP4 receptor with an IC50 and a Ki of 3 nM and 2.35 nM, respectively. KMN-80 is against EP3 receptor with an IC50 of 1.4 μM and >10 μM for all other prostanoid receptors. | ||
| M29480 | BGB-8035 | BTK |
| BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
